Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function

Documenti analoghi

• Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
  di: Kielgast, Urd, et al.
  Pubblicazione: (2011)
• Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients
  di: Kielgast, Urd, et al.
  Pubblicazione: (2010)
• Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
  di: Holst, Jens J., et al.
  Pubblicazione: (2011)
• Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
  di: Knop, Filip K, et al.
  Pubblicazione: (2014)
• Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
  di: Hansen, Christian Stevns, et al.
  Pubblicazione: (2019)